Compare Nomura Holdings Inc (NMR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs TG Therapeutics Inc — how do they compare? Nomura Holdings Inc trades at $9.86 (market cap $28.46B), while TG Therapeutics Inc trades at $49.7 (market cap $7.64B). The key difference: Nomura Holdings Inc is far larger — about 3.7× TG Therapeutics Inc's market cap, and Nomura Holdings Inc pays a 3.31% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NMR | TGTX | |
|---|---|---|
Market Cap | $28.46B | $7.64B |
Sector | Financials | Health |
52-Week High | $10.04 | $59.06 |
52-Week Low | $6.73 | $26.94 |
Dividend Yield | 3.31% | — |
Enterprise Value | — | $7.84B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
